Microscopic of Probiotics Bacteria, lactobacillus bacteria 3d illustration.

HOWARU® Bi-07®

HOWARU® Bi-07®

Bifidobacterium lactis Bi-07®

HOWARU® Bifidobacterium lactis Bi-07® functions harmoniously with other strains like NCFM®, Lpc-37®, and Bl-04® in our HOWARU® Restore blend. Together, they support gut health, lessen the days of gut disruption and support overall digestive health.¹ In two other blends—HOWARU® Protect Kids and HOWARU® Protect Sport—B. lactis Bi-07® has been clinically studied in combination with NCFM® supporting immune function.²

Product Information:
  • ~70 preclinical publications
  • 60+ clinical publications

Health Benefits:
Digestive HealthDigestive
Early Life DevelopmentEarly Life Development
Immune HealthImmune

Bi-07® BLENDS

Learn more about IFF Health Sciences’ Bi-07® blends.

d068b70b62be0324dc4c23d5d77a3a96c39d4691_cropped3

HOWARU® GI Complete

IFF_HS_Our-Products_HOWARU-Protect-Kids_1_Edit

HOWARU® Protect Kids

Sprinting man runner sprinter athlete running shoes and legs on track and field lane run race competing fast panoramic banner background.

HOWARU® Protect Sport

Howaru-Restore-Cropped2

HOWARU® Restore

Bi-07® CLINICAL STUDIES & PUBLICATIONS

Extensive in vitro and in vivo studies support the health-enhancing, probiotic properties of B. lactis Bi-07®. The strain has been investigated in more than 140 scientific publications, including more than 60 clinical trial publications that extend from infants (7 months of age) to aging populations (70 years of age). Bi-07® has a long history of safe use, is well suited for intestinal survival, and has strong adhesion to intestinal cell lines.³⁻⁹

BSS02367

Health Benefit Areas

Each strain’s health benefits are supported by recommended daily doses and peer-reviewed clinical studies.

Click on a Health Benefit to see more studies and learn more.

  1. Supporting Daily Dose: 17B CFU Bl-04®, NCFM®, Bi-07®, Lpc-37®
    Study Reference: Ouwehand AC, et al. Vaccine. 2014;32(4):458-463.
  2. Supporting Daily Dose: 10B CFU Total Bi-07®, Bl-04®, NCFM®, Lpc-37®
    Study Reference: van Zanten G, et al. Microorganisms. 2024; 12(4),796.
LEARN MORE

Supporting Daily Dose: 10B CFU (equal parts) Bi-07®, NCFM®
Study Reference:

LEARN MORE

References: 1. Ouwehand AC et al.; Vaccine. 2014; 2. Leyer GJ et al.;Pediatrics. 2009; 3. Candela M et al.; J Bacteriol. 2007; 4. Candela M et al.; Microbiology. 2009; 5. Candela M, et al.; Microbiology. 2008; 6. Candela M, et al.; Int J Food Microbiol. 2008​; 7. Candela M et al.; J Microbiol Methods. 2008; 8. Candela M et al.; Res. Microbiol. 2005; 9. Candela M et al.; Appl Environ Microbiol. 2011